Clinical trials: IDH Mutation
Astrocytic Tumor, Oligodendroglial Tumor
Study of How Safe and Effective Tarlatamab is in Brain Cancers
This is a phase 2 study to assess how useful study drug tarlatamab is for the treatment of patients with recurrent/refractory oligodendroglioma or astrocytoma with a mutation in the IDH gene.
- Trial name
- NCT06776250
- Testing
- Tarlatamab
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- University Health Network, Toronto
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH…
- Trial name
- NCT04764474
- Testing
- HMPL-306
- Where
- 15 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- Hutchmed
WHO Grade II Glioma
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
- Trial name
- NCT04458272
- Testing
- DS-1001b
- Where
- 11 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Low-grade Glioma, Temozolomide
Trial in Low Grade Glioma Patients: Wait or Treat
The 1635-EORTC-BTG study - Wait or Treat - concerns patients that represent a clinically favorable group of patients with IDHmutated astrocytoma (oligo-symptomatic), without a need for immediate post-operative treatment.
- Conditions
- Low-grade Glioma, Temozolomide, Phase III, Wait or Treat
- Trial name
- IWOT (NCT03763422)
- Testing
- Temozolomide, Radiotherapy, Surgery
- Where
- 45 sites in Australia, Austria and 8 more
- Volunteers
- 19 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioma, Glioma of Brain
Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared
The study aims to assess the direct patient-reported perception (PROs) of individuals affected by IDH-mutant, grade 2 gliomas undergoing radiotherapy or pharmacological treatment with vorasidenib.
- Conditions
- Glioma, Glioma of Brain, Low Grade Glioma of Brain, Low Grade Gliomas
- Trial name
- LGG PRO's (NCT07547163)
- Testing
- Vorasidenib, Radiotherapy, active surveillance
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard…
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
- Trial name
- NCT04603001
- Testing
- LY3410738, Venetoclax, Azacitidine
- Where
- 37 sites in United States, Australia and 10 more
- Volunteers
- 260 people
- Sponsor
- Eli Lilly and Company
Recurrent Glioma, Recurrent Glioblastoma
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma.
- Conditions
- Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor, PTEN Gene Inactivation
- Trial name
- TAC-GReD (NCT04740190)
- Testing
- Talazoparib
- Where
- Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong
IDH1-mutant Glioma, IDH2-mutant Glioma
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
The objective of this study is to determine the safety and tolerability of vorasidenib in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib.
- Trial name
- NCT06478212
- Testing
- Vorasidenib, Temozolomide (TMZ)
- Where
- 28 sites in United States, Austria and 9 more
- Volunteers
- 51 people
- Sponsor
- Institut de Recherches Internationales Servier
Astrocytoma, Oligodendroglioma
A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
Low grade gliomas (LGGs) are the most common primary central nervous system malignancies. Brain surgeries with the most possible extent of resection are endeavored to achieve longer survivals in LGG patients.
- Conditions
- Astrocytoma, Oligodendroglioma, Oligoastrocytoma
- Trial name
- NCT02209428
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Huashan Hospital
High-grade Glioma
How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas
High-grade glioma is the most common primary malignant tumor in central nervous system, and its high tumor heterogeneity is the main cause of tumor progression, treatment resistance and recurrence.
- Trial name
- NCT04908267
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Weiguo Zhang
Glioma, Diffuse Glioma
Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma
The goal of this prospective, single-arm, open-label clinical trial is to evaluate whether 18F-AGX PET imaging can be used to assess early treatment response and metabolic changes in adult patients with recurrent or residual WHO…
- Conditions
- Glioma, Diffuse Glioma, Recurrent Gliomas
- Trial name
- VANGUARD (NCT07469735)
- Testing
- Oral Vorasidenib administered once daily for up to 12 treatment cycles (28 days per cycle) as IDH-targeted therapy in participants with recurrent or residual IDH-mutant diffuse glioma.
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Huashan Hospital
Brain Glioma
Single Photon Emission Computed Tomography/Computed Tomography With Pentavalent 99mTc Dimercaptosuccinic Acid in Patients With Brain Glioma; Correlation With IDH Mutation
The aim of this study is to evaluate the correlation between degree of 99mTc-DMSA (V) uptake at SPECT/CT and IDH mutation in patients with brain glioma.
- Trial name
- NCT05593809
- Testing
- SPECT with pentavalent 99mTc DMSA
- Volunteers
- 40 people
- Sponsor
- Assiut University
Glioma
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
The purpose of this study is to found out if the drug IDH305 is safe and effective in subjects with IDH1 mutant grade II or III glioma that has progressed after observation or radiation therapy.
- Trial name
- NCT02977689
- Testing
- IDH305
- Where
- United States
- Sponsor
- NYU Langone Health
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a…
- Conditions
- Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma
- Trial name
- NCT07301268
- Testing
- Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Myeloproliferative Disorders
Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM)
Retrospective study assessing the impact of IDH1/2, SRSF2 or SF3B1 mutations on event free survival of MPN patients
- Trial name
- CARPEDIEM (NCT06481345)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Cholangiocarcinoma, IDH Mutation
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
This study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma
- Trial name
- adIVO (NCT07260175)
- Testing
- Ivosidenib
- Where
- 15 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma.
- Trial name
- NCT03528642
- Testing
- Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation.
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
- Trial name
- NCT02074839
- Testing
- AG-120
- Where
- 30 sites in United States, France
- Volunteers
- 291 people
- Sponsor
- Institut de Recherches Internationales Servier
Leukemia, Myeloid, Acute
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
The purpose of this study are 1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and, 2.
- Trial name
- NCT02677922
- Testing
- AG-120, Azacitidine, AG-221
- Where
- 49 sites in United States, Australia and 12 more
- Volunteers
- 130 people
- Sponsor
- Celgene
Glioblastoma, Glioblastoma, IDH-Wildtype
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or…
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype
- Trial name
- NCT07089641
- Testing
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center